{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:03:25Z","timestamp":1789563805652,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011699","name":"Siemens Healthineers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijrobp.2026.02.230","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:06:42Z","timestamp":1772093202000},"page":"1471-1479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSA and PSMA Kinetics After PSMA-PET and MR Guided Prostate Stereotactic Body Radiation Therapy With Focal Boost: Results From the Phase 2 PROBE Trial"],"prefix":"10.1016","volume":"125","author":[{"given":"Maneesh","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchismita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Katdare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayak","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Phurailatpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Anaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.02.230_bib0001","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0003","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0004","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[68Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard \u2013 Implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0005","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.ijrobp.2022.07.1185","article-title":"ReIGNITE RT Boost: An international study testing the feasibility, accuracy and reliability of using restriction spectrum imaging (RSI) MRI to guide radiotherapy target volume delineation for prostate cancer tumor boost","volume":"114","author":"Lui","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijrobp.2025.03.033","article-title":"PSMA-PET guided intraprostatic boost in prostate SBRT (PROBE): A phase 2 trial","volume":"125","author":"Singh","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0007","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1200\/JCO.23.00762","article-title":"Prognostic impact of prostate-specific antigen at 6 months after radiotherapy in localized prostate cancer: An individual patient data analysis of randomized trials","volume":"42","author":"Kwak","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110642","article-title":"Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis","volume":"202","author":"Dejonckheere","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0009","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0010","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): Study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0011","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/j.prro.2025.03.008","article-title":"Advancements in prostate cancer radiotherapy: The role of prostate-specific membrane antigen positron emission tomography imaging","volume":"15","author":"Lester-Coll","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0012","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0013","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/pros.24775","article-title":"Impact of definitive radiotherapy on metabolic response measured with 68Ga-PSMA-PET\/CT in patients with intermediate-risk prostate cancer","volume":"84","author":"Onal","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104623","article-title":"\u00ab Augmented radiotherapy \u00bb in the management of high-risk prostate cancer (PCa): A systematic review","volume":"207","author":"Le Gu\u00e9velou","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2023.08.046","article-title":"Trimodality therapy with iodine-125 brachytherapy, external beam radiation therapy, and short- or long-term androgen deprivation therapy for high-risk localized prostate cancer: Results of a multicenter, randomized phase 3 trial (TRIP\/TRIGU0907)","volume":"118","author":"Yorozu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0016","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0017","article-title":"Prostate-specific membrane antigen PET response associates with metastasis-free survival after stereotactic ablative radiation in oligometastatic prostate cancer","volume":"9","author":"Sutera","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0018","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","article-title":"PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis","volume":"64","author":"Ray","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0019","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ijrobp.2019.06.2539","article-title":"Multi-institutional analysis of prostate-specific antigen kinetics after stereotactic body radiation therapy","volume":"105","author":"Jiang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","article-title":"SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer","volume":"6","author":"Kishan","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1748-717X-9-42","article-title":"Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: Comparison of PSA slope and nadir","volume":"9","author":"Anwar","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0022","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00066-017-1239-1","article-title":"Oligometastases in prostate cancer: Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT","volume":"194","author":"Baumann","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijrobp.2025.04.039","article-title":"PSMA MRI Guided prOstate SBRT (ARGOS)\/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) phase I\/II trial","volume":"123","author":"Ramadan","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0024","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16 suppl","key":"10.1016\/j.ijrobp.2026.02.230_bib0025","article-title":"Prognostic impact of PSA nadir (n) \u22650.1 ng\/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative","volume":"41","author":"Ravi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib0026","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00259-019-04581-4","article-title":"The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients","volume":"47","author":"Onal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.prro.2023.05.004","article-title":"Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: 5-year toxicity and biochemical recurrence results from a prospective trial","volume":"13","author":"Maas","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijrobp.2023.05.004","article-title":"Toxicity and patient-reported quality-of-life outcomes after prostate stereotactic body radiation therapy with focal boost to magnetic resonance imaging-identified prostate cancer lesions: Results of a phase 2 trial","volume":"117","author":"Morris","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.230_bib29","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: Planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:08:13Z","timestamp":1785960493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626004177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0360301626004177"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.02.230","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSA and PSMA Kinetics After PSMA-PET and MR Guided Prostate Stereotactic Body Radiation Therapy With Focal Boost: Results From the Phase 2 PROBE Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.02.230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}